Afferent Pharmaceuticals Inc.'s $55 million in series C money gives the firm enough to pay for work that includes the potential phase III trial with AF-219 in idiopathic pulmonary fibrosis (IPF) cough, enabling the firm to "drive this one home ourselves," CEO Kathleen Glaub told BioWorld Today.